Prosthetic valve endocarditis caused by metallo-beta-lactamase-producing Pseudomonas aeruginosa.
Prosthetic valve endocarditis (PVE) caused by Pseudomonas aeruginosa is a rare but life-threatening complication. Early surgical intervention, as well as appropriate antimicrobial therapy, is usually necessary. Recently, problems have arisen regarding infection with P. aeruginosa, which produces metallo-beta-lactamase (MBL) and is resistant to virtually all beta-lactams. This organism has rapidly spread through many countries. Here, we report the first case of successful redo aortic valve replacement using a Prima Plus stentless valve (Edwards Lifesciences, Irvine, CA, USA) followed by a 6-week course of ciprofloxacin and gentamicin for early PVE caused by MBL-producing P. aeruginosa.
Kato
Yasuyuki
Y
Department of Cardiovascular Surgery, Fukui Cardiovascular Center, Shinbo, Fukui, Japan. ayak0511@yahoo.co.jp
Ohashi
Hirokazu
H
Tsutsumi
Yasushi
Y
Murakami
Tadahiro
T
Takahashi
Yosuke
Y
D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001024:Aortic Valve Stenosis / Q000601:surgery*; D002939:Ciprofloxacin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004452:Echocardiography; D004697:Endocarditis, Bacterial / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D005500:Follow-Up Studies; D005839:Gentamicins / Q000627:therapeutic use; D006350:Heart Valve Prosthesis / Q000009:adverse effects* / Q000382:microbiology; D006801:Humans; D008297:Male; D016459:Prosthesis-Related Infections / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D011552:Pseudomonas Infections / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D011550:Pseudomonas aeruginosa / Q000201:enzymology / Q000302:isolation & purification*; D001618:beta-Lactamases / Q000096:biosynthesis*
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D002939:Ciprofloxacin; C533914:metallo-beta-lactamase (VIM-13), Pseudomonas aeruginosa; D001618:beta-Lactamases